IP Library Granted Patent US 8,999,991
Granted Patent B2
US 8,999,991 · App. 14/353,418 · Granted Apr 7, 2015

Inhibitors of the renal outer medullary potassium channel

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,991
App. No.
14/353,418
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.

Claims (35)

1. A compound having structural Formula I:

or a pharmaceutically acceptable salt thereof wherein:

Z 1 is

Z 2 is

R 1 is —H, —CH 3 , —CF 3 , —CHF 2 , —CH 2 F or —CH 2 OH;

R 2 is —H, oxo (═O) or —C 1-6 alkyl;

R 4 is —H, —OH, oxo or —C 1-6 alkyl;

provided that when R 4 is —OH or oxo, then R 2 is not oxo;

R 3 and R 5 are each independently —H or —C 1-6 alkyl; provided that R 3 is absent when R 2 is oxo, and R 5 is absent when R 4 is oxo;

R 1a is —H, halo or —C 1-3 alkyl;

R 1b is —H, halo, —C 1-3 alkyl, —O—C 1-3 alkyl or —COOC 1-3 alkyl;

one of R 2a and R 2b is —CN and the other is —H or —C 1-3 alkyl;

one of R 2c and R 2d is —SO 2 —C 1-3 alkyl and the other is —H or —C 1-3 alkyl;

X 1 , X 2 , X 3 and X 4 are each independently CH or N, provided that only one of X 1 , X 2 , X 3 or X 4 is N;

X 5 , X 6 and X 7 are each independently CH or N, provided that only one of X 5 , X 6 or X 7 is N; and

R a and R b are each independently —H, halo, —C 1-3 alkyl, —O—C 1-3 alkyl or —COOC 1-3 alkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof having structural Formula II:

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein Z 1 is z1-a.

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein R 2 , R 3 and R 5 are each —H, and R 4 is —H, —OH or oxo.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein Z 1 is z1-b.

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof wherein R 2 , R 3 and R 5 are each —H, and R 4 is —H, —OH or oxo.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein Z 1 is

8. The compound of claim 7 or a pharmaceutically acceptable salt thereof wherein Z 1 is

9. The compound of claim 7 or a pharmaceutically acceptable salt thereof wherein Z 1 is

10. The compound of claim 1 which is

6-{2-oxo-4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperazin-1-yl}naphthalene-2-carbonitrile;

6-{4-[(2R)-2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-2-oxopiperazin-1-yl}naphthalene-2-carbonitrile;

6-{4-[2-Hydroxy-2-(6-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-2-oxopiperazin-1-yl}naphthalene-2-carbonitrile;

2-{4-[(2R)-2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-2-oxopiperazin-1-yl}-1,3-benzothiazole-5-carbonitrile; or

2-{4-[(2R)-2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]-2-oxopiperazin-1-yl}-7-methylquinoline-6-carbonitrile;

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprised of a compound of claim 1 and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11 further comprising one or more additional active agent selected from losartan, valsartan, candesartan, olmesartan, telmesartan, eprosartan, irbesartan, azilsartan, hydrochlorothiazide, amlodipine, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, amiloride, spironolactone, epleranone, triamterene or acetazolamide or a pharmaceutically acceptable salt thereof.

13. A method for causing diueresis, natriuresis or both, comprising administering a compound of claim 1 in a therapeutically effective amount to a patient in need thereof.

14. A method for the treatment of one or more disorders selected from hypertension, acute heart failure, and chronic heart failure, pulmonary arterial hypertension comprising administering a compound of claim 1 in a therapeutically effective amount as appropriate, to a patient in need thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2014
From: TANG, HAIFENG; PIO, BARBARA; CHOBANIAN, HARRY R.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 032823/0257 →